SHR-A1912
Antibody–drug conjugate
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook · registrational
Diffuse Large B-Cell Lymphoma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-03.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Diffuse Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-A1912: this drug | Phase 3 | Antibody–drug conjugate | CD79b | not yet graded | No reviewed efficacy summary in this indication | |
| Brentuximab Vedotin | Approved | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| Epcoritamab | Approved | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Rituximab (Rituxan) | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved | Monoclonal antibody | CD19 | Weak signal | NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants | |
| Acalabrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Chidamide | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Ibrutinib | Phase 3 | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Purinostat Mesylate | Phase 3 | Small molecule | HDAC | not yet graded | No reviewed efficacy summary in this indication | |
| Zilovertamab Vedotin | Phase 2/3 | Antibody–drug conjugate | ROR1 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1/2(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SHR-A1912 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.